CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, announced today that it has obtained rights to RNAi delivery technology developed in the laboratory of Professor Judy Lieberman from the CBR Institute for Biomedical Research, a Harvard Medical School Affiliate. The in-licensed technology may enable small interfering RNAs - or siRNAs, the molecules that mediate RNAi - to be targeted with an engineered monoclonal antibody to tumors and other cell types, thereby broadening the scope of Alnylam's delivery technologies for RNAi therapeutics. The in-licensed technology, which was highlighted in an article published in the journal Nature Biotechnology in 2005, represents another potential approach for delivery of RNAi therapeutics with systemic administration.
